Development of a Marslander with crushable shock absorber by virtual and experimental testing

Since the beginning of space exploration, probes have been sent to other planets or moons with the associated challenge of landing on these bodies. For a soft landing several damping methods like landing legs or airbags have been used. A new and potentially less complex and lighter way to reduce the shock loads at touchdown is the use of a crushable shield underneath the lander platform. This crushable shield could be made for example out of an energy absorbing materials like an aluminum honeycomb core with a High Performance Polyethylene cover sheet. The design is particularly advantageous since no moving parts nor other mechanisms are required, thus making the shield very robust and fail safe. The only mission that is currently planned to use this technique is the ESA-mission “ExoMars” which is planned to start in 2016. The development of such a crushable shock absorber implies and requires assessment of materials, manufacturing processes, the setup of a numerical simulation and the experimental validation in a test lab. In an independent research project (Marslander1) a representative engineering mockup of the landing platform has been build and tested at the Landing & Mobility Test Facility (LAMA) to support the numerical simulation model with experimental data. The simulations are based on the explicit Finite Element Method, which discretizes the structure into a defined number of elements, such that each element is assigned a set of equations describing the material properties and applied loads. The goal is to generate a simplified but still accurate model to predict landing scenarios by running Monte Carlo simulations. Results of the above stated development and testing processes will be presented and discussed in this paper

The MASCOT Magnetometer

The Mobile Asteroid Scout (MASCOT) is a small lander on board the Hayabusa2 mission of the Japan Aerospace Exploration Agency to the asteroid 162173 Ryugu. Among the instruments on MASCOT is a fluxgate magnetometer, the MASCOT Magnetometer (MasMag). The magnetometer is a lightweight ( ∼280 g∼280 g ) and low power ( ∼0.5 W∼0.5 W ) triaxial fluxgate magnetometer. Magnetic field measurements during the landing period and during the surface operational phase shall provide information about any intrinsic magnetic field of the asteroid and its remanent magnetization. This could provide important constraints on planet formation and the thermal and aqueous evolution of primitive asteroids.Thomas F. PetersonUnited States. National Aeronautics and Space Administration. Emerging Worlds Progra

第913回千葉医学会例会・第28回麻酔科例会・第56回千葉麻酔懇話会

Introduction Pulmonary Surfactant reduces surface tension in the terminal airways thus facilitating breathing and contributes to host’s innate immunity. Surfactant Proteins (SP) A, B, C and D were recently identified as inherent proteins of the CNS. Aim of the study was to investigate cerebrospinal fluid (CSF) SP levels in hydrocephalus patients compared to normal subjects. Patients and Methods CSF SP A-D levels were quantified using commercially available ELISA kits in 126 patients (0–84 years, mean 39 years). 60 patients without CNS pathologies served as a control group. Hydrocephalus patients were separated in aqueductal stenosis (AQS, n = 24), acute hydrocephalus without aqueductal stenosis (acute HC w/o AQS, n = 16) and idiopathic normal pressure hydrocephalus (NPH, n = 20). Furthermore, six patients with pseudotumor cerebri were investigated. Results SP A—D are present under physiological conditions in human CSF. SP-A is elevated in diseases accompanied by ventricular enlargement (AQS, acute HC w/o AQS) in a significant manner (0.67, 1.21 vs 0.38 ng/ml in control, p<0.001). SP-C is also elevated in hydrocephalic conditions (AQS, acute HC w/o AQS; 0.87, 1.71 vs. 0.48 ng/ml in controls, p<0.001) and in Pseudotumor cerebri (1.26 vs. 0.48 ng/ml in controls, p<0.01). SP-B and SP-D did not show significant alterations. Conclusion The present study confirms the presence of SPs in human CSF. There are significant changes of SP-A and SP-C levels in diseases affecting brain water circulation and elevation of intracranial pressure. Cause of the alterations, underlying regulatory mechanisms, as well as diagnostic and therapeutic consequences of cerebral SP’s requires further thorough investigations

Innovative Ansätze der Daseinsvorsorge in ländlichen Räumen - Lernen von Erfahrungen anderer europäischer Länder für Deutschland (InDaLE)

Das Forschungsprojekt InDaLE (Innovative Ansätze der Daseinsvorsorge in ländlichen Räumen – Lernen von Erfahrungen anderer europäischer Länder für Deutschland) untersuchte innovative Ansätze der Daseinsvorsorge in Österreich, Schweden, Schottland sowie Deutschland und prüfte deren Übertragbarkeit bzw. Anwendbarkeit auf ländliche Räume in Deutschland. Die Broschüre enthält kompakte Projektinformationen, die wichtigsten Untersuchungsergebnisse und unsere darauf basierenden Handlungsempfehlungen

MicroRNAs MiR-17, MiR-20a, and MiR-106b Act in Concert to Modulate E2F Activity on Cell Cycle Arrest during Neuronal Lineage Differentiation of USSC

MicroRNAs are short (∼22 nt) non-coding regulatory RNAs that control gene expression at the post-transcriptional level. Here the functional impact of microRNAs on cell cycle arrest during neuronal lineage differentiation of unrestricted somatic stem cells from human cord blood (USSC) was analyzed./M transition. Most strikingly, miR-17, -20a, and -106b were found to promote cell proliferation by increasing the intracellular activity of E2F transcription factors, despite the fact that miR-17, -20a, and -106b directly target the transcripts that encode for this protein family./S transition

Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis

BACKGROUND Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 12-week and 60-week data from a third phase 3 trial, UNCOVER-1. METHODS We randomly assigned 1296 patients in the UNCOVER-1 trial, 1224 patients in the UNCOVER-2 trial, and 1346 patients in the UNCOVER-3 trial to receive subcutaneous injections of placebo (placebo group), 80 mg of ixekizumab every 2 weeks after a starting dose of 160 mg (2-wk dosing group), or 80 mg of ixekizumab every 4 weeks after a starting dose of 160 mg (4-wk dosing group). Additional cohorts in the UNCOVER-2 and UNCOVER-3 trials were randomly assigned to receive 50 mg of etanercept twice weekly. At week 12 in the UNCOVER-3 trial, the patients entered a long-term extension period during which they received 80 mg of ixekizumab every 4 weeks through week 60; at week 12 in the UNCOVER-1 and UNCOVER-2 trials, the patients who had a response to ixekizumab (defined as a static Physicians Global Assessment [sPGA] score of 0 [clear] or 1 [minimal psoriasis]) were randomly reassigned to receive placebo, 80 mg of ixekizumab every 4 weeks, or 80 mg of ixekizumab every 12 weeks through week 60. Coprimary end points were the percentage of patients who had a score on the sPGA of 0 or 1 and a 75% or greater reduction from baseline in Psoriasis Area and Severity Index (PASI 75) at week 12. RESULTS In the UNCOVER-1 trial, at week 12, the patients had better responses to ixekizumab than to placebo; in the 2-wk dosing group, 81.8% had an sPGA score of 0 or 1 and 89.1% had a PASI 75 response; in the 4-wk dosing group, the respective rates were 76.4% and 82.6%; and in the placebo group, the rates were 3.2% and 3.9% (P<0.001 for all comparisons of ixekizumab with placebo). In the UNCOVER-1 and UNCOVER-2 trials, among the patients who were randomly reassigned at week 12 to receive 80 mg of ixekizumab every 4 weeks, 80 mg of ixekizumab every 12 weeks, or placebo, an sPGA score of 0 or 1 was maintained by 73.8%, 39.0%, and 7.0% of the patients, respectively. Patients in the UNCOVER-3 trial received continuous treatment of ixekizumab from weeks 0 through 60, and at week 60, at least 73% had an sPGA score of 0 or 1 and at least 80% had a PASI 75 response. Adverse events reported during ixekizumab use included neutropenia, candidal infections, and inflammatory bowel disease. CONCLUSIONS In three phase 3 trials involving patients with psoriasis, ixekizumab was effective through 60 weeks of treatment. As with any treatment, the benefits need to be weighed against the risks of adverse events. The efficacy and safety of ixekizumab beyond 60 weeks of treatment are not yet known

Development of a Marslander with crushable shock absorber by virtual and experimental testing

Since the beginning of space exploration, probes have been sent to other planets or moons with the associated challenge of landing on these bodies. For a soft landing several damping methods like landing legs or airbags have been used. A new and potentially less complex and lighter way to reduce the shock loads at touchdown is the use of a crushable shield underneath the lander platform. This crushable shield could be made for example out of an energy absorbing materials like an aluminum honeycomb core with a High Performance Polyethylene cover sheet. The design is particularly advantageous since no moving parts nor other mechanisms are required, thus making the shield very robust and fail safe. The only mission that has used this technique is the ESA/Roscosmos-mission “ExoMars” which started in 2016. The development of such a crushable shock absorber implies and requires assessment of materials, manufacturing processes, the setup of a numerical simulation and the experimental validation in a test lab. In an independent research project (Marslander) a representative engineering mockup of the landing platform has been built and tested at the Landing & Mobility Test Facility (LAMA) to support the numerical simulation model with experimental data. This paper is focusing on the hardware tests. Results of the above stated development and testing processes will be presented and discussed

Association of temporary complete AV block and junctional ectopic tachycardia after surgery for congenital heart disease

Aim: Junctional ectopic tachycardia (JET) is a postoperative complication with a mortality rate of up to 14% after surgery for congenital heart disease. This study evaluated the risk factors of JET and explored the association of postoperative temporary third degree atrioventricular (AV) block and the occurrence of JET. Materials and Methods: Data were collected retrospectively from 1158 patients who underwent surgery for congenital heart disease. Results: The overall incidence of JET was 2.8%. Temporary third degree AV block occurred in 1.6% of cases. Permanent third degree AV block requiring pacemaker implantation occurred in 1% of cases. In all, 56% of patients with JET had temporary AV block (P < 0.001), whereas no case of postoperative JET was reported in patients with permanent AV block (P = 0.56). temporary third degree AV block did not suffer from JET. Conclusions: A correlation between temporary third degree AV block and postoperative JET could be observed. The risk factors identified for JET include younger age groups at the time of surgery, longer aortic cross clamping time and surgical procedures in proximity to the AV node